⭐️ #CROWN at 7 yrs: new benchmark for 1L #ALK+ #NSCLC 🫁Lorlatinib vs crizotinib ✅7-yr PFS 55% vs 3% 🧠No new intracranial progression after 30 mo (~92% IC-free at 7 yrs) @diya_jayram @Jani_Chinmay @HemOncMiami @GlopesMd #lcsm #LungCancer #OncTwitter oncupdates.com/article/crown…

Read our perspective @OncUpdates on the 7-year CROWN data and what the remarkable durability of systemic and intracranial disease control with lorlatinib means for the evolving first-line treatment landscape in ALK+ NSCLC. 🫁🧠 #LungCancer #NSCLC #ALK #PrecisionOncology #lcsm @SylvesterCancer @OncBrothers @Latinamd @GlopesMd @HemOncMiami

From the morning of the best worst day of my life The Whipple operation was physically the hardest thing I’ve ever endured but nearly a decade later I’m cancer-free This photo also captures how my wife said “in sickness and in health” at the altar & committed to every word ❤️

Here are the treatment algorithms we have used during our DLBCL, FL, and Mantle Cell Lymphoma discussions with @mshadman & @DrJFriedberg #Lymphoma #OncTwitter #MedTwitter @OncUpdates @OncoAlert

⭐️History of RAS and the “Invincible Myth of #pancreaticcancer 💜History behind RAS and future directions for Daraxonrasib, all available on recent @OncBrothers episode 👇 #OncTwitter #HemOnc #gism #pcsm #GIOnc #MedTwitter @RevMedicines 🔗Full 🎥👇 oncbrothers.com/ceo-mgoldsmi…

Treatment Algorithm discussion on Follicular and Mantle cell Lymphoma with @DrJFriedberg ✅ Work-up ✅ Upfront Rx & maintenance ✅ Sequencing Full 🗣️: ⭐️ oncbrothers.com/follicular-m… ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #HemeTwitter @OncUpdates @WilmotCancer

⭐️”I think we are going to bend the mortality curve in #pancreaticcancer”. 👉CEO of @RevMedicines joined the @OncBrothers to discuss the story behind Daraxonrasib approval and the company’s mission. #OncTwitter #HemOnc #gism #pcsm #GIOnc #MedTwitter 🎥👇 oncbrothers.com/ceo-mgoldsmi…

Based off LITESPARK-011: Belzutifan + Lenvatinib is now @FDA ✅ in 2L RCC after IO exposure: PhIII: Bel + Len vs. Cabo - mPFS 14.6mos vs. 10.7mos (HR: 0.74) - mOS 33.7mos vs. 28.6mos (HR: 0.85, p=0.061). - AEs: 72% vs. 66% w/ Gr ≥ 3 #OncTwitter #gusm @OncUpdates

⭐️Committed to Daraxonrasib access for everyone who needs it, regardless of ability to pay. CEO of @RevMedicines joined the @OncBrothers to discuss the story behind Daraxonrasib approval and the company’s mission. #OncTwitter #HemOnc #gism Full 🗣️👇 oncbrothers.com/ceo-mgoldsmi…

Based off REFOCUS, lirafugratinib (FGFR inhibitor) is now @FDA ✅ for FGFR2 positive cholangiocarcinoma in 2L and beyond: - ORR: 46% - mDoR: 11.8mos - AEs: Occular toxicity and hyperphosphatemia. #gism #OncTwitter @OncUpdates

⭐️ Switching to camizestrant before progression in ESR1-mutated HR+/HER2− mBC 🎙️ @OncBrothers + 🤩 @elmayermd (@DanaFarber ) break down the new @US_FDA approval and #SERENA-6 #bcsm #BreastCancer #OncTwitter #MedEd #MedX 🎥 Full discussion + summary👇 oncupdates.com/video-podcast…

⭐️ Patient Education: #Daraxonrasib in RAS-mutant #NSCLC @NEJM early-phase data: ✅ Shrinkage in ~1 in 3 prior-treated pts, across RAS types ⚠️ Rash, diarrhea, mouth sores ⌛️RASolve 301 vs chemo ongoing #lcsm #LungCancer #OncTwitter #RAS @sawyer_bawek oncupdates.com/article/darax…

The NHS-Galleri headline: the primary endpoint (fewer stage III/IV cancers) was NOT met. Good specificity and CSO accuracy don't matter much if screening doesn't shift stage or save lives. @OncoAlert @OncBrothers @Larvol

Treatment Algorithm discussion on Diffuse Large B-Cell lymphoma (DLBCL) with @mshadman ✅ Upfront Rx ✅ Sequencing ✅ Side effects/management Full 🗣️: ⭐️ oncbrothers.com/dlbcl-algo-2… ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #HemeTwitter @OncUpdates @OncoAlert

⭐️ #Daraxonrasib in RAS-mutant #NSCLC 👉Patient Education: Here I discuss the recent study published in @NEJM and potential impact. 🔗Full summary 👇 #lcsm #LungCancer #OncTwitter #RAS #HemOnc #Oncology #MedEd #FOAMed #CancerResearch #MedTwitter #MedX @HemOncFellows

How does pharma shape our clinical practice? Clinical to industry transition, Daraxonrasib approval, side effects, and cost implications w/ @RevMedicines CEO #DrMarkGoldsmith Full 🗣️ ⭐️ oncbrothers.com/ceo-mgoldsmi… ⭐️ “Oncology Brothers” podcast @OncUpdates @OncoAlert #gism

🤔Headed to #ASH26? 🗓️ Join us for an in-person @OncBrothers AIO 📅 Sunday, December 13th 🤩 Featured Guest Experts: @DrBrandyeMD @mshadman @lymphomaphilia @SoniSmithMD @DrHKantarjian @RaajitRampal @VincentRK @DrKrinaPatel Register👇 #AdvInOnc26 #OncTwitter #ASH #Hematology